Swiss National Bank Has $5.85 Million Holdings in Amedisys, Inc. (NASDAQ:AMED)

Swiss National Bank grew its position in shares of Amedisys, Inc. (NASDAQ:AMED) by 0.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 64,400 shares of the health services provider’s stock after acquiring an additional 600 shares during the quarter. Swiss National Bank’s holdings in Amedisys were worth $5,847,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently modified their holdings of the company. Blue Trust Inc. increased its stake in Amedisys by 55.1% during the 4th quarter. Blue Trust Inc. now owns 349 shares of the health services provider’s stock valued at $34,000 after purchasing an additional 124 shares in the last quarter. HBW Advisory Services LLC bought a new stake in shares of Amedisys during the fourth quarter worth about $38,000. Versant Capital Management Inc raised its holdings in shares of Amedisys by 68.5% in the 4th quarter. Versant Capital Management Inc now owns 450 shares of the health services provider’s stock worth $41,000 after acquiring an additional 183 shares during the last quarter. KBC Group NV acquired a new stake in shares of Amedisys in the 3rd quarter worth about $63,000. Finally, Venturi Wealth Management LLC lifted its position in Amedisys by 397.4% in the 4th quarter. Venturi Wealth Management LLC now owns 975 shares of the health services provider’s stock valued at $89,000 after acquiring an additional 779 shares in the last quarter. 94.36% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Stephens reissued an “equal weight” rating and issued a $101.00 price objective on shares of Amedisys in a research note on Tuesday, March 4th. Five investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Amedisys presently has an average rating of “Hold” and an average target price of $100.75.

Amedisys Stock Down 0.4 %

Amedisys stock opened at $92.38 on Monday. Amedisys, Inc. has a fifty-two week low of $82.15 and a fifty-two week high of $98.95. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.19 and a current ratio of 1.19. The firm’s 50-day simple moving average is $92.21 and its 200 day simple moving average is $92.56. The stock has a market cap of $3.03 billion, a PE ratio of 36.66, a price-to-earnings-growth ratio of 1.78 and a beta of 0.76.

Amedisys (NASDAQ:AMED) last announced its earnings results on Wednesday, February 26th. The health services provider reported $0.96 earnings per share for the quarter, missing analysts’ consensus estimates of $1.05 by ($0.09). The business had revenue of $598.05 million during the quarter, compared to analysts’ expectations of $602.38 million. Amedisys had a return on equity of 12.20% and a net margin of 3.57%. Research analysts predict that Amedisys, Inc. will post 4.4 EPS for the current fiscal year.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.